Study of BEN301 for autoimmune diseases
Part of Immune system & allergy clinical trials.
This trial tests an experimental treatment called BEN301 for people with autoimmune diseases like systemic sclerosis, rheumatoid arthritis, Sjögren's syndrome, or myositis. It may help if standard treatments haven't worked well enough.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 70 years old.
- You must have one of these conditions: systemic sclerosis, rheumatoid arthritis, Sjögren's syndrome, or certain muscle inflammation disorders.
- Your disease must still be active despite trying other treatments.
- You must have adequate organ function, such as normal blood counts and kidney function.
- You must agree to use effective birth control for one year after treatment.
- You cannot have had certain prior treatments like CAR-T therapy or certain biologics recently.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests a new drug called CC312 in patients with certain autoimmune diseases like lupus, myositis, scleroderma, rheumatoid arthritis, immune thrombocytopenia, or autoimmune hemolytic anemia. The goal is to see if it's safe and how the body handles it.
This trial tests an investigational drug called OL-108 for people with certain autoimmune diseases (lupus, myositis, scleroderma, or vasculitis) that have come back or not responded to standard treatments. The goal is to see if it's safe and if it can help control the disease.
This trial tests a new cell therapy called YTS109 for people with certain autoimmune diseases like lupus that have not improved with standard treatments. It aims to see if this therapy can help control disease activity.
This trial tests a new cell treatment called BCT301 for people with certain autoimmune diseases like lupus or scleroderma that haven't gotten better with standard medicines. It aims to see if this treatment can help control the disease.
This trial is testing an experimental drug for safety in people with certain autoimmune diseases—like myositis, scleroderma, or Sjögren's disease—as well as in healthy volunteers. It aims to find out if the drug is safe enough to study further.
This study tests a new treatment called CC312 for people with lupus, myositis, or scleroderma that hasn't gotten better with standard therapies. It aims to see if CC312 can help control the disease when other treatments have failed.
Hear when a new SSC RA SS IIM trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.